All four inhibitors significantly increased the resistance of wild-type U937 cells to CD4IL10 killing in a dose-dependent manner (Fig. 4D), further confirming the role of ICAM1/LFA-1 interaction for effective AML killing by T cells. The gene discussed is ITGB2; the disease is acute myeloid leukemia.